The Russian Consumer Watchdog, Rospotrebnadzor, announced on Tuesday that the State Research Center of Virology and Biotechnology Vector has created a vaccine for Marburg fever, which has successfully completed preclinical trials, demonstrating its effectiveness.
"Employees of Rospotrebnadzor's Vector State Research Center have developed a vaccine to prevent Marburg fever. The development has already passed preclinical tests, having shown its safety and effectiveness," the statement said.
The vaccine is in a high degree of readiness for clinical trials. The vaccine series is currently being developed, and a package of documents for obtaining the relevant authorization is being prepared, the watchdog said.
Rwanda's Health Minister, Sabin Nsanzimana, announced last Sunday that the country has started vaccinating people against the Marburg virus to combat an outbreak that has resulted in 12 deaths. The vaccination effort will prioritize those "most at risk," including healthcare workers in treatment centers, hospitals, ICUs, and emergency departments, as well as individuals who have been in close contact with confirmed cases.